Cover Image
Market Research Report

Xerostomia - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 619903
Published Content info 44 Pages
Delivery time: 1-2 business days
Price
Back to Top
Xerostomia - Pipeline Review, H2 2018
Published: September 28, 2018 Content info: 44 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Xerostomia - Pipeline Review, H2 2018, provides an overview of the Xerostomia (Mouth and Dental Disorders) pipeline landscape.

Xerostomia is defined as dry mouth resulting from reduced saliva flow. It is caused by medications, age, cancer treatment, injury, dehydration and chewing or smoking tobacco. Symptoms include dysgeusia, fungal infections, bad breath, tongue ulcers, problems speaking and sticky saliva. Treatment includes medications which stimulating saliva production.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Xerostomia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Xerostomia (Mouth and Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Xerostomia (Mouth and Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 5 and 1 respectively.

Xerostomia (Mouth and Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Xerostomia (Mouth and Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Xerostomia (Mouth and Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Xerostomia (Mouth and Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Xerostomia (Mouth and Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Xerostomia (Mouth and Dental Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Xerostomia (Mouth and Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Xerostomia (Mouth and Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10840IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Xerostomia - Overview
    • Xerostomia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Xerostomia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Xerostomia - Companies Involved in Therapeutics Development
    • Capricor Therapeutics Inc
    • Cellix Bio Pvt Ltd
    • Humanetics Corp
    • Icure Pharmaceutical Inc
    • Lamellar Biomedical Ltd
    • MeiraGTx Holdings Plc
  • Xerostomia - Drug Profiles
    • A-00X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-2003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerium oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLX-1561 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Pulmonary Inflammation, Radiodermatitis and Xerostomia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ECF-843 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LMS-611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pilocarpine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Xerostomia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Xerostomia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Xerostomia - Pipeline by Capricor Therapeutics Inc, H2 2018
  • Xerostomia - Pipeline by Cellix Bio Pvt Ltd, H2 2018
  • Xerostomia - Pipeline by Humanetics Corp, H2 2018
  • Xerostomia - Pipeline by Icure Pharmaceutical Inc, H2 2018
  • Xerostomia - Pipeline by Lamellar Biomedical Ltd, H2 2018
  • Xerostomia - Pipeline by MeiraGTx Holdings Plc, H2 2018
  • Xerostomia - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Xerostomia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
Back to Top